Thomas B. King has been appointed to Vivus' board of directors, a biopharmaceutical company working on therapies for unmet medical needs.
King's nearly 40 years of pharmaceutical experience ranges from large to development-stage pharmaceutical companies.
He has served as an independent biotechnology consultant since August 2016.
Previously, King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals.
Prior to this, he served as President, Chief Executive Officer and a member of the board of directors of Cognetix.
From January 1994 to February 2001, King held various senior executive positions at Anesta Corporation, including President and Chief Executive Officer. He was a member of the board of directors until it was acquired by Cephalon.
King currently serves on the board of directors of Faraday Pharmaceuticals ans also also serves as a mentor at SPIRE Bioventures, a multi-disciplinary consortium aiding biotechnology entrepreneurs.
Additionally, he serves as an Advisory Board Member of the University of Colorado BioFrontiers Institute. King received a BA in chemistry from McPherson College and an MBA from the University of Kansas Graduate School of Business.